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Abbreviations	
6MWT	–	6-minute	walk	test	
ANOVA	–	Analysis	of	variance	
ASS	–	Anti-synthetase	syndrome	
CI	–	Confidence	interval	
CPFE	–	Combined	pulmonary	fibrosis	and	emphysema	
DLCO	–	Diffusing	capacity	for	Carbon	Monoxide	
ERES	–	Empirical	rule	effect	size	
ES	–	Effect	size	
FVC	–	Forced	vital	capacity	
HP	–	Hypersensitivity	pneumonitis	
HRQL	–	Health-related	quality	of	life	
ILD	–	Interstitial	lung	disease	
IPF	–	Idiopathic	pulmonary	fibrosis	
K-BILD	–	King’s	Brief	ILD	questionnaire	
MCID	–	Minimal	clinically	important	difference	
NHS	–	National	Health	Service	
NSIP	–	Non-specific	interstitial	pneumonia	
PLCH	–	Pulmonary	Langerhans	cell	Histiocytosis	
RA-UIP	–	Rheumatoid	Arthritis-associated	usual	interstitial	pneumonia	
VAS	–	Visual	analogue	scale	
VASC	–	VAS	for	cough	
VASD	–	VAS	for	dyspnoea	
VASF	–	VAS	for	fatigue	 	
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ABSTRACT		
Background	 Visual	 analogue	 scales	 (VAS)	 are	 simple	 symptom	assessment	 tools	which	have	not	
been	validated	in	interstitial	 lung	disease	(ILD).	Simple	measures	of	ILD	disease	burden	would	be	
valuable	 for	 non-specialist	 clinicians	 monitoring	 disease	 away	 from	 ILD	 specialist	 centres.	 This	
study	aimed	to	validate	VAS	to	assess	change	in	dyspnoea,	cough	and	fatigue	in	ILD,	and	to	define	
the	minimal	clinically	important	difference	(MCID)	for	change	in	these.	
Methods	 64	 patients	with	 ILD	 completed	 VAS	 for	 dyspnoea,	 cough	 and	 fatigue.	 Baseline	 King’s	
Brief	 ILD	 questionnaire	 (K-BILD)	 scores,	 lung	 function	 and	 6-minute	 walk	 test	 results	 were	
collected.	Tests	were	 repeated	3-6	months	 later,	 in	addition	 to	a	7-point	 Likert	 scale.	The	MCID	
was	estimated	using	median	change	 in	VAS	 in	patients	who	reported	“small	but	 just	worthwhile	
change”	 in	 symptoms	 at	 follow-up.	 Methods	 were	 repeated	 in	 a	 validation	 cohort	 of	 31	 ILD	
patients	to	confirm	findings.	
Results	 VAS	 scores	 were	 significantly	 higher	 for	 patients	 who	 reported	 a	 “small	 but	 just	
worthwhile	change”	 in	symptoms	versus	“no	change”	or	“not	worthwhile	change”	 (p<0.01).	The	
MCID	 for	 VAS	Dyspnoea	was	 estimated	 as	 22.0mm	and	 14.5mm	 for	 VAS	 Fatigue.	 These	 results	
were	reproducible	in	the	validation	cohort.	Results	were	not	significant	for	VAS	Cough.	Change	in	
VAS	Dyspnoea	 correlated	with	 change	 in	K-BILD	 (r=-0.51,	 p<0.01),	 forced	 vital	 capacity	 (r=-0.32,	
p=0.01)	and	6-minute	walking	distance	(r=-0.37,	p=0.01).	
Conclusion:	 The	 VAS	 is	 valid	 for	 assessing	 change	 in	 dyspnoea	 and	 fatigue	 in	 ILD.	 The	MCID	 is	
estimated	as	22.0mm	for	dyspnoea	and	14.5mm	for	fatigue.	This	could	be	used	to	monitor	disease	
in	settings	away	from	ILD	specialist	review.	
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INTRODUCTION	1	
	2	
Interstitial	 lung	 diseases	 (ILDs)	 are	 chronic,	 progressive	 disorders	 of	 the	 lung	 parenchyma	3	
associated	with	significant	morbidity	and	mortality1.	Despite	recent	advances	in	ILD	therapies3,	the	4	
care	 of	 a	 large	proportion	of	 ILD	patients	 focuses	 on	 the	management	 of	 dyspnoea,	 cough	 and	5	
fatigue2,4,5.	 Objective	 measures	 of	 lung	 function	 and	 exercise	 testing	 may	 not	 reflect	 patient	6	
experience	of	disease,	and	HRQL	tools	can	be	time	consuming	to	complete	and	interpret,	limiting	7	
their	use.		8	
	9	
Increasingly,	 the	model	of	care	 for	patients	with	 ILD	 is	of	shared	care	between	a	 local,	 referring	10	
centre	 and	 a	 specialist	 ILD	 centre.	 	 This	 care	may	 incorporate	 community	 nurses,	 non-specialist	11	
physicians	 and	 other	 allied	 health	 professionals.	 	 Simple,	 quickly	 completed	 tools	 to	 assess	12	
patients’	 symptoms	 in	 ILD	 would	 be	 valuable	 additions	 to	 clinical	 assessment	 outside	 well-13	
resourced	specialist	centres2.		14	
	15	
The	visual	analogue	scale	(VAS)	is	a	simple	tool	for	assessing	patients’	symptoms,	which	has	been	16	
validated	in	asthma6,	chronic	obstructive	pulmonary	disease7	and	pleural	disease8.	Only	one	study	17	
has	assessed	VAS	in	ILD,	however	the	sample	size	was	small	(n=27)	and	this	did	not	assess	change	18	
over	time9.		19	
				20	
The	 aim	 of	 this	 study	 was	 to	 investigate	 whether	 VAS	 are	 valid	 tools	 for	 assessing	 change	 in	21	
dyspnoea,	 cough	 and	 fatigue	 in	 a	 diverse	 range	 of	 ILD,	 as	 encountered	 in	 a	 heterogeneous	 ILD	22	
clinic,	and	to	identify	the	minimal	change	considered	worthwhile	to	the	patient10,	also	known	as	23	
the	minimum	clinically	important	difference	(MCID)11.		24	
	25	
METHODS	26	
Assessing	validity	of	VAS	and	determining	the	MCID	27	
This	 was	 a	 prospective	 observational	 study.	 Ethical	 approval	 was	 granted	 by	 East	 of	 Scotland	28	
Research	Ethics	Service	and	all	participants	provided	written	consent.	Patients	with	a	range	of	ILDs	29	
were	recruited	consecutively	from	the	Bristol	ILD	service	at	North	Bristol	NHS	Trust	from	January-30	
November	2016.	 Inclusion	criteria	were:	a	diagnosis	of	 ILD,	English	 speaking,	and	a	minimum	of	31	
primary	school	education.	32	
		33	
Patients	completed	written	VAS	for	dyspnoea,	cough	and	fatigue,	lung	function	tests,	a	6-minute	34	
walk	 test	 (6MWT)	 and	 the	 Kings	 Brief	 ILD	 (K-BILD)	 HRQL	 tool.	 VAS	 design	 was	 a	 100mm	35	
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continuous,	horizontal	line	labelled	to	express	symptom	extremes,	based	on	existing	VAS	for	other	36	
respiratory	 disease	 (Figure	 1)12.	 	 	 These	 assessments	 were	 completed	 with	 the	 assistance	 of	37	
respiratory	 physiologists	 supervising	 their	 lung	 function	 testing.	 	 At	 follow-up	 after	 3-6	months,	38	
patients	completed	a	second	VAS,	a	7-point	Likert	scale,	lung	function	tests,	6MWT	and	repeated	39	
the	 K-BILD	 tool	 (Figure	 1).	 Patients	 were	 shown	 their	 previous	 VAS	 scores	 as	 this	 has	 been	40	
demonstrated	to	increase	the	validity	of	patient	reported	outcomes13.		41	
	42	
VAS	scores	were	calculated	by	measuring	the	distance	in	millimetres	from	the	start	of	the	line	to	43	
the	 centre	 of	 the	 point	 recorded	 by	 the	 patient12.	 Change	 in	 VAS	 was	 calculated	 from	 the	44	
difference	 between	 VAS	 score	 at	 initial	 and	 follow-up	 visits.	 In	 analysing	 results,	 the	 relative	45	
change	 in	symptoms	was	explored	by	combining	 improvement	and	deterioration	 together.	 	This	46	
resulted	in	four	categories	for	analysis.		Data	were	categorised	according	to	Likert	scale	response;	47	
“no	change”,	“slight	change	but	not	worthwhile”,	“small	but	just	worthwhile	change”,	and	“large	48	
or	moderate	change”	(Figure	1).	The	MCID	was	estimated	using	the	median	change	in	VAS	in	the	49	
“small	but	just	worthwhile	change”	category.	50	
	51	
Lung	function	and	6MWT	results	were	selected	as	clinical	anchors	to	determine	the	MCID14.		These	52	
are	 validated	 measures	 with	 described	 MCID,	 used	 in	 prognostication	 and	 monitoring	 for	53	
ILD15,18,19.	Patient-based	anchors	were	the	7-point	Likert	scale14,20	and	the	K-BILD	tool17.	54	
	55	
Estimates	 of	 MCID	 were	 compared	 to	 distributional	 methods	 including	 effect	 size	 (ES)	 and	56	
empirical	 rule	 effect	 size	 (ERES)21.	 Distributional	methods	 provide	 statistical	 estimates	 of	MCID	57	
from	underlying	variation	within	the	sample21.	An	ES	of	0.33	has	been	suggested	to	equate	to	the	58	
MCID22,	therefore	ES	MCID	was	estimated	by	multiplying	the	standard	deviation	of	baseline	VAS	59	
score	by	0.33.	The	ERES	is	based	on	the	assumption	that	the	mean	score	is	half	of	the	maximum	60	
score	 (in	 this	 case	 100mm),	 and	 the	 range	 of	 the	 outcome	measure	 is	 6	 standard	 deviations21.	61	
Therefore	the	ERES	MCID	was	calculated	by	dividing	100	by	6.		Additionally,	patients	estimated	the	62	
change	 in	VAS	which	 they	 considered	 “meaningful”	 to	provide	patient-opinion	estimated	MCID.	63	
Results	were	compared	with	anchor	and	distribution-based	estimates.	64	
	65	
Statistical	Analysis	66	
Statistical	 analyses	 were	 performed	 using	 MiniTab17	 Statistical	 software23.	 	 All	 patients	 who	67	
completed	 data	 collection	 at	 follow-up	 were	 included	 in	 the	 analyses.	 Data	 were	 assessed	 for	68	
normality	and	one	way	analysis	of	variance	(ANOVA)	was	used	to	assess	for	differences	between	69	
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groups	categorised	by	Likert	score.	Moods	Median	test	was	used	for	non-parametric	data.	Median	70	
change	in	VAS	for	patients	reporting	a	“small	but	 just	worthwhile	change”	was	used	to	calculate	71	
MCID.	72	
	73	
Correlations	between	change	 in	VAS	and	change	 in	forced	vital	capacity	 (FVC),	diffusing	capacity	74	
for	 carbon	 monoxide	 (DLCO),	 6MWT	 and	 K-BILD	 scores	 were	 assessed	 using	 Spearman’s	 Rank	75	
correlation	coefficient.	The	strength	of	correlations	were	determined	according	to	absolute	values	76	
of	 the	 coefficient;	 large	 (r>0.5),	 moderate	 (r=0.5-0.3)	 and	 small	 (r=0.1-0.3)24.	 	 Any	 influence	 of	77	
symptom	 severity	 on	 patients’	 perceived	 change	 in	 symptoms	 was	 assessed	 by	 examining	78	
correlation	between	baseline	VAS	and	subsequent	change	in	VAS.	79	
	80	
A	sample	size	of	8	patients	in	the	Likert	category	“small	but	just	worthwhile	change”	was	required	81	
to	give	a	power	of	90%	to	detect	a	change	in	VAS	scores	at	a	p-value	of	0.05,	calculated	from	the	82	
MCID	and	standard	deviation	reported	 in	a	study	of	dyspnoea	related	to	pleural	disease8,25.	The	83	
validity	of	the	MCID	was	assessed	by	repeating	these	methods	in	a	second	cohort.	The	estimated	84	
MCID	 was	 assessed	 for	 similarity	 with	 the	 initial	 cohort	 using	 the	 Mann-Whitney	 U	 test.	 	 The	85	
recruitment	cohort	sizes	were	pragmatically	selected	to	maximise	the	chances	of	achieving	this	in	86	
the	absence	of	published	data	in	this	area	for	ILD.	87	
	88	
	89	
Outcomes	90	
The	primary	outcome	of	 the	study	was	 the	MCID	estimated	 from	the	median	change	 in	VAS	 for	91	
patients	reporting	a	“small	but	 just	worthwhile	change”	on	the	7-point	Likert	scale	at	 follow-up.	92	
Other	 pre-specified	 secondary	 outcomes	 included	 correlation	 of	 change	 in	 VAS	 with	 change	 in	93	
FVC,	DLCO,	 6MWT	and	K-BILD,	 and	 comparison	of	 the	 estimated	MCID	with	patient-opinion	 and	94	
distributional	methods.	95	
	96	
RESULTS	97	
Validating	VAS	and	determining	the	MCID	98	
Of	131	patients	recruited	for	this	study,	one	was	excluded	due	to	visual	impairment.		Completed	99	
data	were	available	for	95/130	(73%)	of	patients	enrolled	(2	died,	33	did	not	attend	for	follow-up	100	
during	the	study	period).	The	first	64	completed	data	sets	were	assigned	to	the	initial	cohort,	and	101	
subsequent	31	to	the	validation	cohort	(Figure	2).	102	
	103	
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The	baseline	characteristics	of	patients	in	both	cohorts	were	comparable	and	are	shown	in	Table	104	
1.	Mean	age	 in	the	 initial	cohort	was	66	years,	41%	were	female,	97%	were	Caucasian,	and	31%	105	
had	Idiopathic	Pulmonary	Fibrosis	(IPF).	Mean	FVC	was	83%	predicted	and	mean	DLCO	was	55.7%	106	
predicted.		107	
	108	
Overall,	there	were	30	patients	with	IPF	and	67	with	non-IPF	fibrotic	lung	disease	included	in	the	109	
analyses.		There	was	no	difference	between	these	groups	for	baseline	or	interval	change	in	VASD,	110	
VASC	or	VASF	(Supplementary	Table	1).		There	was	no	difference	in	the	proportion	of	respondents	111	
reporting	 “small	 but	 just	worthwhile	 change”	 in	 symptoms	who	had	 IPF	when	compared	 to	 the	112	
proportion	of	respondents	with	IPF	in	the	overall	cohort	(38.6%	vs	30.9%,	p=0.304).	113	
	114	
Anchor-based	MCID	115	
Likert	scale	selections	were	similarly	distributed	for	dyspnoea,	fatigue	and	cough	(Table	2).	Most	116	
patients	 reported	 “no	 change”	 in	 symptoms	whilst	 the	 lowest	 numbers	 reported	 “moderate	 or	117	
large	change”.	Similar	numbers	reported	a	“small	but	just	worthwhile	change”	for	all	symptoms.	118	
	119	
Median	changes	in	VAS	categorised	by	Likert	scale	response	are	shown	in	Table	2.	Median	change	120	
in	 VAS	 increased	 as	 Likert	 response	 increased	 for	 all	 symptoms.	 The	 MCID	 for	 change	 in	 VAS	121	
Dyspnoea	 (VASD)	was	 22.0mm,	 equating	 to	 a	 “small	 but	 just	worthwhile	 change”	 on	 the	 Likert	122	
scale.	Moods	median	 showed	 statistically	 significant	 differences	 in	 change	 in	 VASD	 between	 all	123	
Likert	groups	(p<0.001,	95%	CI,	12-35mm)	(Table	2,	Figure	3A).	124	
	125	
The	 MCID	 for	 change	 in	 VAS	 Fatigue	 (VASF)	 was	 14.5mm.	 There	 were	 statistically	 significant	126	
differences	 for	 change	 in	 VASF	 between	 all	 Likert	 groups	 (p=0.006,	 95%	 CI,	 8-20mm)	 (Table	 2,	127	
Figure	3B).		There	were	no	significant	between-group	differences	in	change	in	VAS	Cough	(VASC)	128	
(p=0.061)	(Figure	3C),	therefore	the	MCID	could	not	be	determined.		129	
	130	
Distribution-based	estimates	of	MCID	were	lower	than	anchor-based	estimates	for	VASD	(7.7mm-	131	
8.4mm	and	22.0mm	respectively),	but	values	were	similar	for	VASF	(8.4mm-	9.0mm	and	14.5mm	132	
respectively)	 (Table	 3).	 Patient-opinion	 and	 anchor-based	 estimates	 of	 VASD	MCID	were	 similar	133	
(20.5mm	 and	 22.0mm	 respectively),	 but	 patient-opinion	 was	 higher	 for	 VASF	 (28.0mm	 and	134	
14.5mm)	(Table	3).	135	
	136	
Correlations	137	
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Change	in	VASD	correlated	moderately	with	change	in	FVC%	(r=-0.319)	and	6MWD	(r=-0.365),	but	138	
there	was	no	correlation	with	change	in	DLCO%	(Table	4).	The	correlations	between	change	in	VASF	139	
and	6MWD	were	moderate	(r=-0.349),	but	insignificant	for	FVC%	and	DLCO%	(Table	4).	Change	in	140	
VASD,	 VASF	 and	 VASC	 all	 moderately	 correlated	 with	 K-BILD	 scores	 (r=-0.363—0.506).	 The	141	
strongest	correlation	was	between	VASD	and	dyspnoea-specific	K-BILD	domains	(r=-0.557)	(Figure	142	
4).	There	was	no	correlation	between	VASC	and	K-BILD	cough	domains,	 lung	 function	or	6MWD	143	
(Table	4).		There	was	no	correlation	between	any	VAS	and	age.	144	
	145	
There	was	no	correlation	between	initial	VASD	and	VASF	and	subsequent	change	in	VAS	(r=-0.075	146	
and	 r=-0.184	 respectively).	 	 There	 was	 moderate	 correlation	 between	 VASC	 and	 subsequent	147	
change	in	VAS	(r=-0.364,	p<0.01).		148	
	149	
Validation	of	the	MCID	150	
Baseline	 characteristics	 for	 the	 validation	 cohort	 of	 31	 patients	 are	 shown	 in	 Table	 1.	 Anchor-151	
based	estimates	of	the	MCID	were	26.5mm	for	change	in	VASD	and	11.0mm	for	change	in	VASF,	152	
for	the	validation	cohort	(Table	3).	These	were	not	significantly	different	for	both	VASD	(p=0.66,	153	
95%	CI,	-19-13mm)	and	VASF	(p=0.77,	95%	CI,	-7-16mm).	154	
	155	
DISCUSSION		156	
This	is	the	first	study	to	demonstrate	that	VAS	are	valid	tools	for	assessing	change	in	dyspnoea	and	157	
fatigue	 in	 ILD.	 	 The	MCID	 for	 change	 in	VASD	 is	22.0mm	and	VASF	 is	14.5mm.	 	VAS	are	 simple,	158	
quick	and	easy	 to	use	patient-reported	measures,	which	could	have	value	 in	clinical	assessment	159	
outside	specialist	ILD	centres.		The	validity	of	VAS	and	their	responsiveness	to	change	were	shown	160	
by	correlation	with	validated	measures	of	disease	status.		161	
	162	
The	authors	recognise	that	there	are	some	limitations,	including	those	inherent	to	a	single	centre	163	
study,	therefore	caution	should	be	taken	before	applying	these	findings	to	other	populations.	33	164	
patients	did	not	return	for	follow-up	during	the	study	period	due	to	the	regional	status	of	the	ILD	165	
service	patient.		Additionally,	this	work	was	conducted	in	a	heterogeneous	cohort,	including	some	166	
patients	with	sarcoidosis,	which	may	have	influenced	the	findings	of	the	VASF.		These	patients	all	167	
had	fibrotic	parenchymal	disease,	however	and	the	cohort	was	selected	to	represent	a	pragmatic,	168	
real-world	clinical	spectrum	reviewed	in	ILD	centres.		The	grouping	together	of	IPF,	a	progressive	169	
disease,	with	non-IPF	fibrotic	 lung	diseases	has	the	potential	to	 influence	these	results,	however	170	
no	statistically	significant	differences	were	seen	between	the	VAS	for	these	groups	at	baseline	or	171	
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on	follow-up.		Likewise,	IPF	was	not	over-represented	in	the	group	of	respondents	reporting	“small	172	
but	just	worthwhile	change”	in	symptoms	at	follow-up.	173	
	174	
The	 selection	 of	 clinical	 parameters	 to	 which	 to	 compare	 the	 VAS	 was	 based	 on	 those	 used	175	
routinely	 in	 this	 ILD	centre.	 	As	such,	we	did	not	compare	VASC	and	VASF	to	specific	cough	and	176	
fatigue	questionnaires.		This	may	limit	the	interpretation	of	our	results,	however	the	VASC	did	not	177	
reveal	significant	changes	over	time.		The	K-BILD	QoL	tool,	while	not	specifically	designed	to	assess	178	
fatigue,	 does	 give	 a	 holistic	 assessment	 of	 patient	 symptoms	 and	 as	 such	 is	 an	 appropriate	179	
comparator	to	the	VASF	and	VASD.	There	are	also	limitations	inherent	to	the	use	of	VAS.	 	These	180	
measures	 are	 subject	 to	 “end	 of	 scale”	 bias,	 wherein	 respondents	 are	 less	 likely	 to	 use	 the	181	
extreme	ends	of	the	scale	to	assess	their	health	status.		Likewise,	it	is	possible	that	while	VAS	are	182	
measured	 to	 the	 nearest	 millimetre,	 respondents	 are	 unable	 to	 make	 such	 fine	 distinctions	 in	183	
position	along	a	line.		This	should	not	prevent	their	application	as	a	simple	tool,	easily	interpreted	184	
by	clinicians	without	experience	or	expertise	in	specialist	QoL	tools.	185	
	186	
Dyspnoea	has	been	reported	as	the	principal	and	most	debilitating	symptom	in	ILD4,	therefore	its	187	
assessment	 is	essential	 in	disease	management.	The	estimated	MCID	of	22.0mm,	confirmed	in	a	188	
second	 cohort	of	31	patients,	 is	 similar	 to	 reports	of	dyspnoea	 in	pleural	disease8,	 asthma6	and	189	
COPD7.		VASD	demonstrated	responsiveness	to	change	in	ILD	status	by	correlation	with	changes	in	190	
validated	measures,	 including	 FVC,	 6MWD	 and	 K-BILD15,27.	 In	 contrast,	 change	 in	 VASD	 did	 not	191	
correlate	 with	 change	 in	 DLCO%.	 Although	 DLCO%	 is	 used	 to	 describe	 IPF	 severity	 and	 predict	192	
disease	progression18,	its	variability	compared	with	FVC28	limits	its	use	as	a	primary	outcome	in	IPF	193	
clinical	trials29,30.		194	
	195	
Dyspnoea	is	influenced	by	several	factors	in	addition	to	the	pulmonary	restriction	and	reduced	gas	196	
exchange	observed	in	ILD,	and	the	relationships	between	dyspnoea	and	FVC,	DLCO	and	6MWD	are	197	
complex2,27.	Previous	studies	have	found	symptom	domains	of	quality	of	life	assessments	did	not	198	
correlate	 with	 FVC%	 and	 DLCO%31,32,	 whereas	 other	 studies	 have	 found	 weak	 but	 statistically	199	
significant	associations1,19,33.	A	clinical	trial	in	patients	with	IPF	found	significant	reductions	in	FVC	200	
were	 not	 associated	 with	 reduced	 dyspnoea	 scores29.	 A	 possible	 explanation	 could	 be	 that	201	
patients	 with	 more	 severe	 disease	 status	 limit	 their	 activity	 levels	 and	 therefore	 under-report	202	
symptom	deterioration31.		This	is	reflected	in	the	low	mean	values	for	VASD	observed	in	this	study	203	
(34mm).	204	
		205	
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Our	 findings	 show	VASD	 is	 also	associated	with	 validated	patient-reported	measures.	Change	 in	206	
VASD	score	was	associated	with	change	in	Likert	score,	demonstrating	its	ability	to	reflect	patient	207	
experience14.	 Furthermore	 change	 in	 VASD	 correlated	 with	 change	 in	 K-BILD	 scores,	 consistent	208	
with	 previous	 studies	 which	 found	 correlations	 between	 VASD	 and	 other	 quality	 of	 life	209	
assessments	 (r=-0.61)33.	 Finally,	 patient-estimated	MCID	 was	 similar	 to	 anchor-based	 methods,	210	
providing	further	evidence	that	VASD	accurately	reflects	patient	opinion.	211	
	212	
Distributional	methods	 underestimated	 the	MCID	 for	 VASD,	 consistent	with	 a	 study	which	 also	213	
compared	 distributional	 and	 anchor-based	 methods8.	 Distributional	 approaches	 have	 been	214	
criticised	as	 they	do	not	use	clinical	anchors	and	provide	a	purely	 statistical	estimation	of	MCID	215	
based	 on	 the	 underlying	 variation	 within	 the	 sample348,14.	 In	 this	 study	 we	 used	 the	 optimal	216	
approach	recommended	for	determining	the	MCID,	with	increased	emphasis	on	anchor	methods,	217	
and	support	provided	by	distributional	methods	and	patient	opinion14,17.	218	
		219	
The	results	of	our	study	suggest	that	VAS	is	valid	for	assessing	change	in	fatigue	in	patients	with	220	
ILD,	and	the	estimated	MCID	is	14.5mm.	Median	VAS	fatigue	(VASF)	score	was	higher	for	patients	221	
reporting	a	“small	but	just	worthwhile	change”	compared	to	“no	change”,	and	median	change	in	222	
VASF	 increased	 in	 association	with	 increased	 Likert	 scale	 response.	 Additionally,	 the	MCID	was	223	
confirmed	 in	 the	 validation	 cohort.	 However,	 there	 were	 wide	 and	 overlapping	 95%	 CI	 for	 all	224	
groups,	 particularly	 those	 reporting	 changes,	 and	 a	 lack	 of	 correlation	 of	 VASF	 with	 other	225	
measures.	 These	 results	 are	 consistent	 with	 a	 study	 which	 found	 VASF	 was	 less	 sensitive	 than	226	
other	scales	for	assessing	fatigue,	whereas	VASD	was	superior35.	227	
	228	
There	 is	 a	 paucity	 of	 studies	which	 have	 looked	 specifically	 at	 the	 prevalence	 of	 fatigue	 in	 ILD,	229	
although	 it	 is	 widely	 understood	 to	 be	 common	 based	 on	 quality	 of	 life	 studies5.	 Predictors	 of	230	
fatigue	 have	 been	 modelled	 for	 IPF	 but	 could	 not	 be	 identified	 for	 sarcoidosis,	 indicating	 the	231	
diverse	 manifestation	 of	 the	 symptom	 amongst	 different	 ILDs36.	 Although	 VASF	 has	 not	 been	232	
investigated	in	ILD,	it	has	been	assessed	in	a	range	of	diseases	including	rheumatoid	arthiritis37	and	233	
cancer38	 and	was	 validated	 for	 patients	 with	 sleep	 disorders39.	 	 	 VASF	 has	 also	 been	 shown	 to	234	
correlate	with	objective	measures	including	exercise	testing.	However,	the	study	populations	used	235	
were	small	and	included	male	athletes35	and	Chinese	female	students40,	limiting	their	applicability	236	
to	our	study	population.		237	
	238	
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The	 correlation	 observed	 between	 VASF	 and	 6MWD	 could	 be	 due	 to	 the	 inclusion	 of	 physical	239	
muscle	 weakness	 secondary	 to	 de-conditioning	 within	 the	 subjective	 perception	 of	 fatigue5.	240	
Therefore	 although	 VASF	was	 able	 to	 detect	 change	 in	 fatigue,	 given	 the	 complexity	 of	 fatigue	241	
symptoms	and	the	mixed	results	observed	in	this	study,	further	research	is	required	before	VASF	242	
can	be	recommended	for	clinical	use	in	patients	with	ILD.	243	
	244	
In	 this	 study	 VASC	 was	 unable	 to	 detect	 change	 in	 cough	 symptoms.	 Previous	 studies	 have	245	
demonstrated	a	 lack	of	 correlation	between	cough	 rates	and	 lung	 function	 tests41	 and	between	246	
subjective	and	objective	measures	of	cough42,43.	Cough	is	a	complex	symptom	of	ILD,	and	there	are	247	
likely	 to	 be	 alternative	 causes	 such	 as	 rhinitis	 and	 gastro-oesophageal	 reflux	 in	 the	 patients	248	
studied44.	 Patients	 have	 identified	 cough	 as	 a	 fundamental	 symptom	 of	 ILD45,	 therefore	 it	 is	249	
important	to	establish	valid	methods	for	its	assessment.		250	
	251	
This	is	the	first	study	to	assess	change	in	VASD,	VASF	and	VASC	in	ILD.	The	sample	size	was	larger	252	
than	 previous	 studies,	 and	 longitudinal	 study	 design	 allowed	 for	 responsiveness	 of	 VAS	 to	 be	253	
determined,	and	calculated	MCIDs	were	validated	in	a	separate	cohort.	This	study	was	performed	254	
in	a	busy	out-patient	service	and	demonstrates	the	practicality	of	the	VAS	for	routine	use	 in	 ILD	255	
clinics.	256	
	257	
	258	
Conclusion	259	
This	 study	 has	 shown	 the	 VAS	 is	 a	 valid	 and	 clinically	 relevant	 tool	 for	 assessing	 change	 in	260	
dyspnoea	 and	 fatigue	 in	 patients	 with	 ILD.	 These	 scales	 correlate	 with	 recognised	 markers	 of	261	
disease,	including	K-BILD	and	pulmonary	physiology	tests.		The	MCID	for	change	in	VAS	is	22.0mm	262	
for	 dyspnoea	 and	 14.5mm	 for	 fatigue.	 VAS	 is	 a	 quick	 and	 simple	 tool	 which	 could	 be	 used	263	
alongside	lung	function	tests	and	quality	of	life	assessments	to	establish	disease	progression	and	264	
could	represent	a	useful	adjunct	to	clinical	assessment	in	non-specialist	settings	where	more	time-265	
consuming	measures	are	not	practical.	266	
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Tables	381	
 382	
Table	1		Baseline	characteristics	by	cohort	
	 Initial	 cohort	
(N=64)	
Validation	 Cohort	
(N=31)	
Mean	age,	years	(SD)	 66	(14)	 68	(12)	
Mean	follow-up,	days	(SD)	 127	(58)	 116	(37)	
Women,	n	(%)	 26	(41)	 13	(42)	
Race/ethnicity,	n	(%)	 	 	
					Caucasian	 62	(97)	 31	(100)	
					Other*	 2	(3)	 0	(0)	
Smoking	status,	n	(%)	 	 	
					Never	smoked	 31	(48)	 16	(52)	
					Ex-smoker	 31	(48)	 15	(48)	
					Current	smoker	 2	(3)	 0	(0)	
Mean	baseline	VAS	score,	mm	(SD)	 	 	
					VAS	Dyspnoea	 34	(23)	 35	(24)	
					VAS	Cough	 43	(26)	 41	(30)	
					VAS	Fatigue	 43	(27)	 40	(25)	
Mean	baseline	lung	function	tests	 	 	
					FVC,	L	(SD)	 2.8	(1.0)	 2.9	(1.2)	
					FVC,	%	predicted	(SD)	 82.5	(18.8)	 88.9	(20.1)	
					DLCO,	%	predicted	(SD)	 55.7	(19.6)	 56.6	(22.4)	
					6MWD,	m	(SD)	 340	(111.6)	 320.8	(96.0)	
					Nadir	oxygen	saturations	at	6MWT,	%	(SD)	 87.6	(5.8)	 88	(5.3)	
Mean	baseline	K-BILD	score	(SD)	 62.6	(21.4)	 62.5	(22.7)	
ILD	diagnosis,	n	(%)	 	 	
					IPF	 20	(31)	 10	(32)	
					HP	 9	(14)	 7	(23)	
					Sarcoidosis	(fibrotic	parenchymal	disease)	 8	(13)	 4	(13)	
					CT-ILD	 7	(11)	 3	(10)	
					NSIP	 5	(8)	 3	(10)	
					Other	 10	(16)	 4	(13)	
					Unclassifiable	 5	(8)	 0	(0)	
Definition	of	abbreviations:	FVC,	forced	vital	capacity;	DLCO,	diffusing	capacity	for	carbon	monoxide;	6MWD,	
6-minute	walk	distance;	K-BILD,	King’s	Brief	Interstitial	Lung	Disease	questionnaire;	CT-ILD,	Connective	Tissue	
Disease-associated	 ILD;	 HP,	 Hypersensitivity	 Pneumonitis;	 IPF,	 Idiopathic	 pulmonary	 fibrosis;	 NSIP,	 non-
specific	interstitial	pneumonia.		
*South	Asian	patients	originating	from	India,	Pakistan	or	Bangladesh	
 383	
 384	
 385	
 386	
 387	
 388	
 389	
 390	
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 391	
 392	
 393	
 394	
 395	
Table	2			Median	change	in	VAS	categorised	by	Likert	scale	response	
	 Likert	Scale	Response	 Number	 of	
patients	(%)	
Median	 change	
VAS	(mm)	
95%	 CI	
(mm)	
VAS	
Dyspnoea	
No	change	 25	(39)	 4.0	 2-6	
Slight	change	but	not	worthwhile	 16	(25)	 9.0	 6-10	
Small	but	just	worthwhile	change*	 17	(27)	 22.0	 12-35	
Large	or	moderate	change	 6	(9)	 30.0	 12-64	
VAS	
Fatigue	
No	change	 17	(27)	 4.0	 2-9	
Slight	change	but	not	worthwhile	 19	(30)	 11.0	 5-17	
Small	but	just	worthwhile	change*	 18	(28)	 14.5	 8-20	
Large	or	moderate	change	 10	(16)	 20.5	 6-49	
VAS	
Cough	
No	change	 18	(28)	 7.0	 3-18	
Slight	change	but	not	worthwhile	 19	(30)	 10.0	 7-17	
Small	but	just	worthwhile	change*	 18	(28)	 18.0	 15-32	
Large	or	moderate	change	 9	(14)	 23.0	 11-77	
Definition	of	abbreviations:	VAS,	visual	analogue	scale;	CI,	confidence	interval.	
*Median	change	in	VAS	score	for	patients	who	reported	a	“small	but	just	worthwhile	change”	in	symptoms	
on	the	Likert	scale	was	used	to	estimate	the	MCID	
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Table	 3	 	 	 Anchor,	 Distributional	 and	 Patient-opinion	 estimates	 of	 the	 minimal	 clinically	
important	difference	(MCID)*	
	 ES	 ERES	 Anchor-based	 Patient-	opinion	
VAS	Dyspnoea	 7.7	 8.4	 22.0	 20.5	
VAS	Fatigue	 9.0	 8.4	 14.5	 28.0	
N=64	
Definition	 of	 abbreviations:	MCID,	minimal	 clinically	 important	 difference;	 ES,	 effect	 size;	 ERES,	 empirical	
rule	effect	size	
*MCID	in	mm	
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Table	 4	 	 	 Spearman’s	 correlation	 coefficients	 between	 change	 in	 VAS	 and	 change	 in	 other	
measures	
	 VAS	Dyspnoea	 VAS	Fatigue	 VAS	Cough	
FVC%	 -0.319	(p=0.010)	 -0.275	(p=0.028)	 		0.06	(p=0.635)	
DLCO%	 -0.201	(p=0.124)	 -0.186	(p=0.156)	 -0.012	(p=0.928)	
6MWD	 -0.365	(p=0.007)	 -0.349	(p=0.010)	 	0.045	(p=0.751)	
KBILD	Overall	 -0.506	(p=0.000)	 -0.500	(p=0.000)	 -0.363	(p=0.003)	
KBILD	Specific	 -0.557	(p=0.000)	 -0.423	(p=0.000)	 -0.217	(p=0.085)	
N=64	
Definition	 of	 abbreviations:	 VAS,	 visual	 analogue	 scale;	 FVC,	 forced	 vital	 capacity;	 DLCO,	 carbon	monoxide	
diffusing	capacity;	6MWD,	6-minute	walk	distance;	K-BILD,	King’s	Brief	Interstitial	Lung	Disease	Questionnaire.	
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Supplementary	Table	1	
Comparison	of	IPF	and	non-IPF	fibrotic	lung	disease	VAS	at	baseline	and	interval	change	
Visual	Analogue	Scales	in	ILD	
17	
	
	 IPF	 Non-IPF		 p-value	
Mean	baseline	VAS	Dyspnoea,	mm	(SD)	 36	(19)	 34	(25)	 0.459	
Mean	baseline	VAS	Cough,	mm	(SD)	 38	(20)	 44	(29)	 0.490	
Mean	baseline	VAS	Fatigue,	mm	(SD)	 43	(21)	 42	(29)	 0.674	
Change	in	VAS	Dyspnoea,	mm	(SD)	 3	(17)	 2	(21)	 0.603	
Change	in	VAS	Cough,	mm	(SD)	 2	(20)	 -5	(29)	 0.298	
Change	in	VAS	Fatigue,	mm	(SD)	 9	(19)	 2	(21)	 0.124	
Definition	of	abbreviations:	VAS,	visual	analogue	scale;	IPF,	Idiopathic	Pulmonary	Fibrosis.	
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Visual	Analogue	Scales	in	ILD	
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Figure	Legends	402	
	403	
Figure	1			Visual	Analogue	Scales	and	7-point	Likert	scale	used	to	assess	change	in	dyspnoea,	cough	404	
and	fatigue.	405	
	406	
Figure	2			Study	flowchart	407	
Data	collection	was	performed	between	January-November	2016.	33	patients	who	did	not	return	408	
for	follow-up	during	this	period	were	excluded	from	analyses	409	
	410	
Figure	3			Comparison	of	change	in	VAS	in	patients	categorised	by	Likert	scale	response.		411	
The	boxes	show	the	median	values	and	25-75%	percentiles,	and	lines	show	0-90%	percentiles.	A)	412	
Change	 in	 VAS	 dyspnoea,	 significant	 between-group	 difference	 (p=0.000).	 B)	 Change	 in	 VAS	413	
Fatigue,	 significant	 between-group	 difference	 (p=0.006)	 C)	 Change	 in	 VAS	 Cough,	 no	 significant	414	
difference	between	groups	(p=0.061).	Definition	of	abbreviations:	VAS,	visual	analogue	scale.	415	
	416	
Figure	4	 	 	Relationship	between	change	 in	VAS	Dyspnoea	and	dyspnoea-specific	 components	of	417	
the	K-BILD	questionnaire.		418	
Circles	represent	individual	data	points	(change	VASD	and	change	in	dyspnoea	components	of	K-419	
BILD).	Solid	like	represents	the	line	of	best	fit.	420	
*Spearman	Rank	correlation	coefficient	421	
Definition	of	abbreviations:	VAS,	visual	analogue	scale;	K-BILD,	King’s	Brief	Interstitial	Lung	Disease	422	
Questionnaire.	423	
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